Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7763505 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: SAD, MAD, and Food Effect in Healthy Participants | EXPERIMENTAL | Healthy participants will receive RO7763505 or matching placebo. |
| Part 2: In Stable CAD Participants | EXPERIMENTAL | Participants with stable CAD will receive RO7763505 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| RO7763505 | DRUG | Participants will receive RO7763505 as per the schedule described in the protocol. |
| Placebo | DRUG | Participants will receive matching placebo as per the schedule described in the protocol. |
Inclusion Criteria: Part 1: * Healthy biologically male and female participants of nonchildbearing potential or childbearing potential with no clinically relevant findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgica...
RO7763505 is an investigational small molecule being developed for stable coronary artery disease. It is currently in Phase 1 clinical development, with a study evaluating its effects and safety in healthy people and people with stable heart disease.
RO7763505 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and how it works in participants.
RO7763505 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 study is currently active but not recruiting participants.
RO7763505 is being studied in one active Phase 1 clinical trial with the identifier NCT07495813. The trial is a randomized, double-blind, controlled study enrolling 196 participants, including healthy volunteers and people with stable coronary artery disease, conducted in the Netherlands.
No alternative names for RO7763505 have been identified. The drug is known by its development code RO7763505 and is being investigated by Roche for stable coronary artery disease.